Main Menu

The Institute of Cancer Research, London, is one of the world’s most influential cancer research organisations. Today, read about a knighthood for Professor Mel Greaves, our new cancer drug access report or our childhood leukaemia appeal.

Back to top
  • “The future’s bright” – Professor Udai Banerji reflects on the evolution of anticancer drugs

    “The future’s bright” – Professor Udai Banerji reflects on the evolution of anticancer drugs

    Marking his promotion to Professor after 18 years at the ICR, Professor Banerji gave his inaugural lecture to packed lecture theatres across our two sites. We heard him talk about his work on the development of new anticancer drugs, and where he sees the field going next.

    Read more
  • High-precision radiotherapy can safely treat prostate cancer spread

    High-precision radiotherapy can safely treat prostate cancer spread

    Men with ‘high risk’ prostate cancer can safely receive high-dose radiotherapy to kill cancer cells that have spread into neighbouring lymph nodes, a new study reports.

    Read more
  • New AI ‘shapeshift’ test identifies women with ‘very high risk’ ovarian cancer

    New AI ‘shapeshift’ test identifies women with ‘very high risk’ ovarian cancer

    Scientists have developed an artificial intelligence test that scans the shapes of tumour cells to pick out women with especially aggressive ovarian cancer.

    Read more
  • What does the NHS Long Term Plan really mean for childhood cancer?

    What does the NHS Long Term Plan really mean for childhood cancer?

    The NHS released their Long Term Plan yesterday – much of the media coverage focused on the news about genetic testing for childhood cancer. We look at the plan and whether it will really deliver for children with cancer.

    Read more
  • Protein found more in advanced prostate cancer could be key to preventing drug resistance

    Protein found more in advanced prostate cancer could be key to preventing drug resistance

    A cancer-driving protein is found in the tumours of men with advanced prostate cancer after treatment with hormone drugs, but rarely found in early-stage disease, a new study shows.

    Read more
  • Help us make childhood leukaemia a thing of the past

    Help us make childhood leukaemia a thing of the past

    Over the past 40 years, Professor Mel Greaves has been carrying out research to increase our understanding of childhood leukaemia, particularly how the most common form of this disease, acute lymphoblastic leukaemia (ALL), develops.

    Support us
1/6

Childhood leukaemia appeal

Our latest research shows that within the next decade, we can make acute lymphoblastic leukaemia preventable. Your support will help us make this disease a thing of the past.

Donate

ICR values

Our values – developed together as an organisation – make it clear how each and every one of us work to meet our mission – to make the discoveries that defeat cancer.

Find out more

Share your story

We always want to hear from people who have a cancer story to share. Get in touch and help raise awareness of our research.

Find out more

How we work with industry

We work in close partnership with industry to take results into the clinic as soon as possible, and make sure our research delivers for cancer patients.

Find out more

The Drug Discoverer

Our Chief Executive and President, Professor Paul Workman, shares his experiences on his blog, The Drug Discoverer.

Find out more

Our scientific discoveries

For more than 100 years, the ICR has played an important role in shaping understanding of cancer and how it can be treated.

Find out more
We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.